"Are you not frustrated and confused that every single piece of clinical data on RECAF has come out of the company itself or some unknown foreign scientist out on his own???!?!?"
No, I am not. What is important is what Abbott does with their license. It is all about potential revenue. It is nice to hear about high sensitivity results from outside sources, but those are, in reality, just words and numbers. In due time, Abbott will say something to their investors about the sensitivity of the RECAF technology, for early cancer screening. Perhaps it will be a joint BioCurex/Abbott announcement. It could even happen at the first milestone. That is when it will mean something in terms of an early detection, cancer screening test that Abbott plans to market. That is also when we will get Wall Street's attention. For we as investors, this investment is presently all about achieving the first milestone, and that could be announced shortly. I will use the word "shortly" because that is the word Dr. Moro used when he referred to Erthang's average price. Dr. Moro said "we will be over that shortly." If the Abbott deal first milestone is achieved, it gives good assurance that we are "home free" on this investment. What really should be important to BioCurex investors is that some of the RECAF technology has been in the hands of the number one diagnostic company in the world for almost a year. There is a provision in the deal that Abbott can return the license upon 90 days notice and, so far, that has not happened. Be patient and hang on, because everyone is going to like what happens next after the first milestone is achieved. kag
News 
Market Data 
Discover 
